Amneal Pharmaceuticals received a Buy rating from Truist Financial on August 1, 2025, noting that the company benefits from Trump-era tariffs and AI trends.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amneal Pharmaceuticals received a Buy rating from Truist Financial on August 1, 2025, noting that the company benefits from Trump-era tariffs and AI trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amneal Pharmaceuticals, Inc.
American publicly traded generics and specialty pharmaceutical company
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
Coverage
Newest first; wire copies grouped- Insider MonkeyTruist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best strong buy stocks to buy under $10. In a report released